
Asia Green Biotechnology Corp. Stock Analysis ASIA.CN
Asia Green Biotechnology Corp. is an early stage international agri-technology company, which engages in the development, evaluation, testing, application, and supply to the market of proprietary organic hybridization technology. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-01-24. The firm is focused on the development, evaluation, testing, application and, ultimately, supply to the market of organic hybridization technology and certain products derived from that technology (the Technology). The firm is engaged in planting, growth and harvesting of new and valuable strains of hemp and related crops in commercial quantities under the terms of the license agreement with InPlanta Biotechnology Inc. (InPlanta) and the evaluation and development of medicinal and related cannabinoid extracts under the terms of license agreements with Swysh Inc. (Swysh), and Pathway Rx Corp (Pathway Rx).
Read More Asia Green Biotechnology Corp (ASIA.CN) Chart
Key Statistics of Asia Green Biotechnology Corp (ASIA.CN)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
CAD0.02Volume
10.00KP/E Ratio (TTM)
-52 Week Range
Market Cap
550.00KAvg. Volume
43.11KDividend Yield
-Financial Metrics & Statements of Asia Green Biotechnology Corp (ASIA.CN)
FAQ's for Asia Green Biotechnology Corp (ASIA.CN)
- According to Musaffa’s Shariah screening methodology, Asia Green Biotechnology Corp (ASIA.CN) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.